Abstract:AIM:To examine the effect of celecoxib on tumor growth and angiogenesis in an orthotopic implantation tumor model of colon cancer.METHODS:Human colorectal adenocarcinoma HT-29 cells were implanted subcutaneously in nude mice. Four groups of animals received different doses of celecoxib after tumor implantation. After 42 days, all animals were evaluated for changes in body weight, the volume and weight of colorectal tumors, and tumor growth inhibition. The content of prostaglandin E(2) (PGE(2)) in the tumor tissue homogenate was estimated by radioimmunoassay (RIA). Cyclooxygenase-2 (COX-2) and CD34 expression in tumor tissue was assessed by immunohistochemistry, and the microvessel density (MVD) of tumor tissue was determined. Apoptosis of the tumor cells was detected by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL). The expression of vascular endothelial growth factor (VEGF) mRNA and matrix metalloproteinase-2 (MMP-2) mRNA extracted from the tumor tissue was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR).RESULTS:There was no statistically significant change in the animals' body weight between the treatment groups. However, with increasing doses of celecoxib, the volume and weight of the tumor decreased. The rates of tumor growth inhibition for the L (low), M (medium) and H (high) groups were 25.30%, 38.80%, and 76.92%, respectively, which were significant compared to the C (control) group. There were significant differences in COX-2 expression in the tumor tissue between all groups, except between the L and M groups. Celecoxib exposure also reduced PGE2 levels in the tumor tissue homogenates. The level of PGE(2) correlated to the weight of tumor (r=0.8814, P < 0.05) and to COX-2 expression (r=0.8249, Puse < 0.05). Compared to the control group, the tumor cells from celecoxib-treated mice had a significantly higher apoptotic index. Celecoxib also decreased CD34(+) expression in tumors from treated mice. There were significant differences in the MVD between all groups except between groups H and M. Celecoxib significantly reduced the expression of VEGF and MMP-2 mRNA in the group H but not in L and M groups. The MVD in tumor tissue was closely related to the PGE2 levels, as well as the expression of VEGF and MMP-2 mRNA (r = 0.9006, r = 0.8573 and r = 0.6427, respectively; P < 0.05).CONCLUSIONS:By inhibiting COX-2, PGE(2) synthesis, and VEGF and MMP-2 mRNA expression in tumor tissue, celecoxib enhances tumor cell apoptosis, thereby inhibiting the growth and angiogenesis of orthotopically implanted tumors in a mouse model of human colorectal cancer.

Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.

Celecoxib Attenuates Hepatosteatosis by Impairing De Novo Lipogenesis Via Akt-dependent Lipogenic Pathway

Apoptosis Induced by Celecoxib Eombinated with Cisplatin in Human Osteosarcoma Cell Line MG-63 Via Down-Regulation of PI3K/Akt

Potent Cell Growth Inhibitory Effects in Hepatitis B Virus X Protein Positive Hepatocellular Carcinoma Cells by the Selective Cyclooxygenase-2 Inhibitor Celecoxib

Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity

Effect of Cyclooxygenase-2 Inhibitor on CD4+ CD25+ Regulatory T Cells in Mouse Hepatocellular Carcinoma

Parecoxib inhibits tumorigenesis and angiogenesis in hepatocellular carcinoma through ERK–VEGF/MMPs signaling pathway

Celecoxib induces apoptosis via a mitochondria‑dependent pathway in the H22 mouse hepatoma cell line.

Celecoxib Downregulates Cd133 Expression Through Inhibition of the Wnt Signaling Pathway in Colon Cancer Cells

Meloxicam Suppresses Hepatocellular Carcinoma Cell Proliferation and Migration by Targeting COX-2/PGE2-regulated Activation of the Β-Catenin Signaling Pathway.

Osu-03012, A Novel Celecoxib Derivative, Induces Reactive Oxygen Species-Related Autophagy In Hepatocellular Carcinoma

Celecoxib Inhibits Tumor Growth and Angiogenesis in an Orthotopic Implantation Tumor Model of Human Colon Cancer.

Osu-03012, A Novel Celecoxib Derivative, Induces A Unique Autophagy-Like Cell Death In Human Hepatocellular Carcinoma Cells

c-Met inhibition is required for the celecoxib-attenuated stemness property of human colorectal cancer cells

Celecoxib Enhances Anticancer Effect of Cisplatin and Induces Anoikis in Osteosarcoma Via PI3K/Akt Pathway.

Overexpression of Cyclooxygenase-2 in Human HepG2, Bel-7402 and SMMC-7721 Hepatoma Cell Lines and Mechanism of Cyclooxygenase-2 Selective Inhibitor Celecoxib-Induced Cell Growth Inhibition and Apoptosis

Antiproliferative effects of celecoxib in Hep-2 cells through telomerase inhibition and induction of apoptosis.

The Molecular Mechanisms of Celecoxib in Tumor Development

Celecoxib Inhibits Interleukin-6/Interleukin-6 Receptor–Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cells

Cyclooxygenase-2 Inhibitor is a Robust Enhancer of Anticancer Agents Against Hepatocellular Carcinoma Multicellular Spheroids

The Effects of Inhibited the Proliferation by Celecoxib in Human Primary Hepatic Cancer Xenograft of Nude Mice in Vivo